Definity (Perflutren Lipid Microspheres) Patent Expiration, LOE Window & CMS Spending
Definity (Perflutren Lipid Microspheres) by Lantheus Medical Imaging: FDA Orange Book core substance LOE 2035-12-28 (last listed 2037-05-04), 0 AB generics, $7.0M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Lantheus Medical Imaging |
| FDA Application & Pathway | N021064 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-12-28 |
| Last Listed Patent or Exclusivity Date | 2037-05-04 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $7.0M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $7.0M |
| Reported Wholesale Price Change (CA SB 17) | 7 WAC filings (max 23.6% 2-yr change) |